Management Strategies for CLN2 Disease
Стратегии ведения пациентов с болезнью CLN2
2017-02-04
SCID: 54.1/69d3k2p9
Discuss with AI
CLN2 diseasemultidisciplinary managementneuronal ceroid lipofuscinosis type 2pediatric palliative caretripeptidyl peptidase 1 deficiency
Figures from the paper
Abstract (AI)
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.
Key Findings
1
A survey of 24 disease experts found globally consistent management goals and strategies guided by pediatric palliative care principles.
2
CLN2 disease lacks formal management guidelines and disease-specific evidence, so current care relies largely on childhood neurodisability experience.
3
Management priorities evolve with disease progression, shifting from preserving function early to maintaining quality of life later.
4
Multidisciplinary care is identified as critical for optimal management of CLN2 disease.
5
The findings provide an initial foundation for developing consensus-based management guidelines for CLN2 disease.
Research Object
CLN2 disease (neuronal ceroid lipofuscinosis type 2)
Research Subject
disease management goals and strategies across the progression of CLN2 disease
Publication Details
Publication Date
2017-02-04
Journal
Publisher
ISSN
Cited by
126
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis2016
Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function2013
Cited by4
Lysosomal storage disease overview2018
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients2021
Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease2020
Visual perception and macular integrity in non-classical CLN2 disease2022